GRN163L

DRUG2 trials

Sponsors

Geron Corporation

Conditions

Breast CancerChronic Lymphoproliferative Diseases

Phase 1

Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

CompletedNCT00124189

Geron CorporationChronic Lymphoproliferative Diseases

Start: 2005-07-31End: 2013-03-31Target: 48Updated: 2015-12-24

A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer

CompletedNCT00732056

Geron CorporationBreast Cancer

Start: 2008-07-31End: 2012-03-31Updated: 2015-12-24